Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 2/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | BMP1 | P13497 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26089233 | 1.00 | POLB (0.46) | POLBCTDSP1MMP2MMP3BMP1 | |
| SCHEMBL26436580 | 0.74 | CTSK (0.57) | MEN1KMT2A | |
| SCHEMBL23422180 | 0.73 | POLB (0.47) | POLBCTDSP1MMP2MMP3BMP1 | |
| SCHEMBL23422179 | 0.73 | POLB (0.47) | POLBCTDSP1MMP2MMP3BMP1 | |
| SCHEMBL23309858 | 0.73 | GPR139 (0.48) | POLBMEN1KMT2ALMNAMAPK1 | |
| SCHEMBL23309862 | 0.73 | GPR139 (0.48) | POLBMEN1KMT2ALMNAMAPK1 | |
| SCHEMBL4897016 | 0.72 | MMP3 (0.48) | POLBCTDSP1MMP2MMP3BMP1 | |
| SCHEMBL10144081 | 0.69 | MAPT (0.57) | MMP2MMP3BMP1MEN1KMT2A | |
| SCHEMBL13399391 | 0.66 | RECQL (0.50) | POLBCTDSP1MEN1KMT2ARECQL | |
| SCHEMBL16714831 | 0.66 | MEN1 (0.69) | POLBCTDSP1MEN1KMT2ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127046-A1 | G9a INHIBITOR | RIKEN (JP) | 2023-04-27 | — | — | US | disclosed |
| EP-4066896-A1 | G9A INHIBITOR | RIKEN (JP) | 2022-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127046-A1 | G9a INHIBITOR | EZH2, BMI1, DOT1L | POLB 1427/4885CTDSP1 4076/4885MMP2 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.